Prevention of incident fracture of Osteoporosis in Japan(Multi-center Randomized Trial with Risedronate and VitaminK2).
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Mar 2011
At a glance
- Drugs Risedronic acid (Primary) ; Vitamin K
- Indications Fracture; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms JOINT-03
- 30 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 07 May 2008 New trial record.